r.rotation.to⌕ Search stocks, people, sectors
Request a free account

Follow the people · Insider

CG

Carl L. Gordon

Insider · Director · BLSM

Carl L. Gordon files insider transactions with the SEC as a director of BlossomHill Therapeutics (BLSM). We hold 2 disclosed purchases and sales filed since 18 May 2006, 2 of them in the last 90 days.

  • Files forBLSM
  • Disclosed buys and sells2 in all, 2 in the last 90 days
  • Last disclosure12 August 2026

Positions held

20 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 6 August 2026 — 10 August 2026Director · BlossomHill Therapeutics (BLSM)6 Form 4 lines · source: SEC Form 4
  • Filed 23 July 2026 — 27 July 2026Director · Scribe Therapeutics (SCTX)4 Form 4 lines · source: SEC Form 4
  • Filed 4 November 2021 — 2 January 2026Director · Compass Therapeutics (CMPX)16 Form 4 lines · source: SEC Form 4
  • Filed 13 April 2020 — 21 November 2025Director · Keros Therapeutics (KROS)15 Form 4 lines · source: SEC Form 4
  • Filed 12 September 2024 — 18 February 2025Director and 10% owner · MBX Biosciences (MBX)12 Form 4 lines · source: SEC Form 4
  • Filed 19 June 2020 — 1 November 2024Director · Lomond Therapeutics Holdings (NONE)14 Form 4 lines · source: SEC Form 4
  • Filed 15 September 2020 — 21 August 2024Director and 10% owner · Adicet Bio (ACET)36 Form 4 lines · source: SEC Form 4
  • Filed 9 February 2021 — 16 July 2024Director and 10% owner · Terns Pharmaceuticals (TERN)26 Form 4 lines · source: SEC Form 4
  • Filed 15 May 2024 — 15 May 202410% owner · BiomX (PHGE)3 Form 4 lines · source: SEC Form 4
  • Filed 2 December 2020 — 3 April 2024Director and 10% owner · Kinnate Biopharma (KNTE)45 Form 4 lines · source: SEC Form 4
  • Filed 6 October 2021 — 14 February 2024Director and 10% owner · Theseus Pharmaceuticals (THRX)24 Form 4 lines · source: SEC Form 4
  • Filed 30 January 2024 — 30 January 2024Director and 10% owner · ArriVent Biopharma (AVBP)10 Form 4 lines · source: SEC Form 4
  • Filed 4 October 2021 — 4 October 2021Director and 10% owner · Gemini Therapeutics, Inc. /DE (GMTX)1 Form 4 line · source: SEC Form 4
  • Filed 23 April 2020 — 16 June 2021Director and 10% owner · Oric Pharmaceuticals (ORIC)23 Form 4 lines · source: SEC Form 4
  • Filed 24 June 2019 — 22 January 2021Director and 10% owner · Prevail Therapeutics (PRVL)8 Form 4 lines · source: SEC Form 4
  • Filed 22 April 2019 — 15 June 2020Director · Turning Point Therapeutics (TPTX)7 Form 4 lines · source: SEC Form 4
  • Filed 11 February 2019 — 10 May 2019Director and 10% owner · Alector (ALEC)28 Form 4 lines · source: SEC Form 4
  • Filed 30 January 2018 — 22 June 2018Director · ARMO BioSciences (ARMO)13 Form 4 lines · source: SEC Form 4
  • Filed 15 November 2017 — 5 June 2018Director · Arsanis (ASNS)14 Form 4 lines · source: SEC Form 4
  • Filed 5 May 2016 — 18 May 2017Director · Intellia Therapeutics (NTLA)8 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.